In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
Author:
Affiliation:
1. BeiGene USA, Inc. San Mateo CA USA
2. BeiGene (Beijing) Co., Ltd Beijing China
Publisher
Wiley
Subject
General Pharmacology, Toxicology and Pharmaceutics,Neurology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.870
Reference45 articles.
1. Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies
2. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
3. Imbruvica. [package insert]. Sunnyvale CA:Pharmacyclics LLC;2018.
4. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
5. Brukinsa. [package insert]. San Mateo CA:BeiGene Ltd.;2019.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2024-08-21
2. Simultaneous Determination of Ibrutinib, Dihydroxydiol Ibrutinib, and Zanubrutinib in Human Plasma by Liquid Chromatography–Mass Spectrometry/Mass Spectrometry;Therapeutic Drug Monitoring;2024-03-21
3. Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models;European Journal of Pharmaceutical Sciences;2023-10
4. The Structure–property Relationships of Clinically Approved Protein Kinase Inhibitors;Current Medicinal Chemistry;2023-07
5. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation;Cancer Chemotherapy and Pharmacology;2023-06-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3